Inactive Instrument

News Immunoprecise Antibodies Ltd Toronto S.E.

Equities

TQY

CA87588T2020

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments	Apr. 12	CI
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications	Mar. 28	BU
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments	Mar. 20	BU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024	Mar. 15	AQ
Transcript : ImmunoPrecise Antibodies Ltd., Q3 2024 Earnings Call, Mar 14, 2024	Mar. 14
ImmunoPrecise Antibodies : Q3 2024 Earnings Presentation	Mar. 14	PU
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*	Mar. 14	BU
IMMUNOPRECISE ANTIBODIES : MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED JANUARY 31, 2024 - Form 6-K	Mar. 14	PU
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 14	CI
ImmunoPrecise Antibodies : Q3 2024 Earnings Transcript	Mar. 13	PU
IPA's subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology	Mar. 08	AQ
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology	Mar. 07	BU
Certain Warrants of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	Mar. 05	CI
Certain Stock Options of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	Mar. 05	CI
Certain Common Shares of ImmunoPrecise Antibodies Ltd. are subject to a Lock-Up Agreement Ending on 6-MAR-2024.	Mar. 05	CI
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024	Mar. 04	BU
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024	Dec. 15	AQ
ImmunoPrecise Antibodies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 14	CI
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*	Dec. 14	BU
Transcript : ImmunoPrecise Antibodies Ltd., Q2 2024 Earnings Call, Dec 14, 2023	Dec. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immunoprecise Antibodies Ltd Toronto S.E.

Equities

TQY

CA87588T2020

Summary

Filters